2 unknown, 1 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Primary Gout: new trials by email Literature Review of Primary Gout trials Research Report on Primary Gout
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers SHR4640 - Primary Gout, Hyperuricemia | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2020-10-01 | 2020-10-14 |
| Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Diacerein, Colchicine, Febuxostat - Primary Gout | Phase 4 | Completed | Tongji Hospital | 96 | 2013-01-01 | 2014-05-08 |
Hyperuricemia (2) · Gout (1)
Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Arthritis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Crystal Arthropathies (1) · Genetic Diseases, Inborn (1) · Joint Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Musculoskeletal Diseases (1) · Nutritional and Metabolic Diseases (1) · Purine-Pyrimidine Metabolism, Inborn Errors (1) · Rheumatic Diseases (1)
Febuxostat (2) · Colchicine (1) · diacerein (1) · ruzinurad (1)
Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Tongji Hospital (1)
China (2)
Shaoxian HU, Doctor (1) · Zourong Ruan, PhD (1)